Compare Capri Holdings Ltd (CPRI) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Crispr Therapeutics AG — how do they compare? Capri Holdings Ltd trades at $14.69 (market cap $1.67B), while Crispr Therapeutics AG trades at $53 (market cap $4.88B). The key difference: Crispr Therapeutics AG is far larger — about 2.9× Capri Holdings Ltd's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Crispr Therapeutics AG for 77 Days on average.
| CPRI | CRSP | |
|---|---|---|
Market Cap | $1.67B | $4.88B |
Volume | 3,722,279 | 2,861,747 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $74.92 |
52-Week Low | $12.71 | $44.34 |
Typical Hold Time | 41 Days | 77 Days |
Enterprise Value | $2.95B | $3.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% today, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with strong profitability metrics (62.71% gross margin, 252.89% ROE) but concerning fundamental trends including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Recent news highlights management's focus on brand revitalization and second-half growth expectations for Michael Kors and Jimmy Choo brands.
The investment case balances attractive valuation (P/S 0.51) against substantial operational challenges. Analyst consensus leans neutral with a $20.57 price target representing 42% upside, but investors face risks from continued revenue declines, high debt levels, and the ongoing Michael Kors turnaround execution. The stock offers potential value if management's growth initiatives gain traction in the second half of 2026.
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
